Key facts
- It has raised $10K; the latest was Early Stage VC ($10K) in Oct 2025.
- Notable investors include Founder First Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SokoLife
- ·The full record, as it builds
Funding rounds
No funding rounds for SokoLife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SokoLife
Manufacturer of xeno-derived biomaterial products designed for use in surgical and wound care applications. The company utilizes advanced tissue engineering and scalable manufacturing processes in controlled facilities, maintains rigorous quality standards, and supports a range of clinical needs including pediatric cardiovascular surgery, reconstructive surgery, and wound care, enabling healthcare providers to access reliable and biocompatible materials for complex medical procedures.
- Sector
- Healthcare
- HQ
- Eugene, OR, United States
- Founded
- 2022
- Website
- xenotissuepatch.com/
- Ownership
- Privately Held (backing)
SokoLife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SokoLife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SokoLife in its N-PORT filings yet. We sweep new filings monthly.